San Francisco, CA, United States of America

Son Minh Pham

This inventor holds 26 USPTO granted patents and 31 published patent applications, plus 3 CIPO patents and 2 EPO patents, primarily in Cancer Treatment Compounds. Top assignees: Nuvation Bio Inc., Medivation Technologies, Inc., Auransa Inc.. Active years: 2017-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Son Minh Pham. Retrieved from https://idiyas.com/inventor/son-minh-pham

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 26 (Patent Applications = 31)

% Patents Active = 73.1

CIPO Patents = 3 (Patent Applications = 7)

EPO Patents = 2 (Patent Applications = 33)

Average Co-Inventor Count = 7.0

ph-index = 3

Forward Citations = 32(Granted Patents)

Company Filing History:

Medivation Technologies, Inc.

where one patent can have more than one assignee

Years Active: 2017-2026

Loading Chart...

Areas of Expertise:

Heterocyclic Compounds

Cancer Treatment

Nuclear Hormone Receptor

BET Inhibitors

Adenosine Antagonists

Wee1 Inhibitors

Piperlongumine Derivatives

Pyrazinecarboxamide

Diarylhydantoin

Kinase Inhibitors

1,8-Naphthyridinone

Dihydropyridinones

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12655131 - Pyrazinecarboxamide analog compounds for use in treating cancer (2026-06-16),

2. 12398121 - Anti-cancer nuclear hormone receptor-targeting compounds (2025-08-26),

3. 12208141 - Anti-cancer nuclear hormone receptor-targeting compounds (2025-01-28),

4. 12006314 - Anti-cancer nuclear hormone receptor-targeting compounds (2024-06-11),

5. 11952349 - Anti-cancer nuclear hormone receptor-targeting compounds (2024-04-09),

6. 11834458 - Anti-cancer nuclear hormone receptor-targeting compounds (2023-12-05),

7. 11826430 - Anti-cancer nuclear hormone receptor-targeting compounds (2023-11-28),

8. 11702401 - Compounds and methods of use (2023-07-18),

9. 11584756 - Heterocyclic compounds as BET inhibitors (2023-02-21),

10. 11485725 - Derivatives of piperlongumine and uses thereof (2022-11-01),

11. 11332473 - Substituted pyrazolo[3,4-d]pyrimidines as Wee1 inhibitors (2022-05-17),

12. 11306071 - Heterocyclic compounds as adenosine antagonists (2022-04-19),

13. 11299493 - Heterocyclic compounds and uses thereof (2022-04-12),

14. 11292782 - Diarylhydantoin compounds and methods of use thereof (2022-04-05),

15. 11254670 - 1,8-naphthyridinone compounds and uses thereof (2022-02-22),

Title: The Innovative Contributions of Son Minh Pham in Cancer Research

Introduction: Son Minh Pham, based in San Francisco, CA, is a prominent inventor recognized for his significant contributions to cancer research. With an impressive portfolio of 24 patents, his work focuses on developing novel anti-cancer compounds derived from nuclear hormone receptor binders. His innovative approach seeks to enhance therapeutic options for cancer treatment.

Latest Patents: Son Minh Pham's latest patents demonstrate his commitment to advancing cancer therapeutics. His disclosures include anti-cancer nuclear hormone receptor-targeting compounds. These compounds are derived from nuclear steroid receptor binders and include a variety of formulations such as tautomers, stereoisomers, and pharmaceutically acceptable salts. Each patent aims to provide valuable insights into methods for their use and preparation, catering to the pressing need for effective cancer treatments.

Career Highlights: Throughout his career, Son Minh Pham has made substantial contributions in the pharmaceutical sector. He has worked with notable companies, including Nuvation Bio Inc. and Medivation Technologies, Inc. His dedication to innovation has established him as a leading figure in the field of cancer research.

Collaborations: Collaboration has been a key aspect of Son Minh Pham's career. He has worked alongside talented individuals such as Sarvajit Chakravarty and Jayakanth Kankanala. These partnerships have fostered an environment of creativity and shared expertise, paving the way for groundbreaking advancements in the fight against cancer.

Conclusion: In conclusion, Son Minh Pham is a distinguished inventor whose work has profound implications for cancer treatment. With 24 patents to his name, his contributions through anti-cancer nuclear hormone receptor-targeting compounds exemplify his pioneering spirit. As he continues his innovative journey, his research stands to benefit countless individuals battling cancer worldwide.

Profile summary based on public USPTO records.